earnings
confidence high
sentiment positive
materiality 0.80
Adaptive Biotechnologies Q3 revenue $46.4M (+22%); MRD revenue up 52%; net loss narrows to $32.1M
Adaptive Biotechnologies Corp
2024-Q3 EPS reported
-$0.86
revenue$131,498,000
- Revenue $46.4M (+22% YoY); MRD revenue $37.5M (+52%); Immune Medicine $9.0M (-32%).
- Net loss $32.1M vs $50.3M YoY; Adjusted EBITDA loss $14.3M vs $29.8M.
- clonoSEQ test volume 19,600 (+30%); Medicare gapfill rate raised 17% to $2,007/test.
- MRD revenue guidance raised to $143-145M (prev. $140-145M); op. expense guidance cut to $335-340M.
- Cash, cash equivalents and marketable securities $267.2M; interest expense on revenue interest purchase $2.9M.